Price T Rowe Associates Inc Biotechnology

Price T Rowe Associates Inc

$812 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
SCPH Sc Pharmaceuticals Inc.	$90.7M	$40,000 0.0% of portfolio	15,143	Q4 2024 New
CHRS Coherus Bio Sciences, Inc.	$59.1M	$39,000 0.0% of portfolio	48,153	Q1 2025 Added 19.88%
PROK Prokidney Corp Ord Shs Cl A(Cy	$47.4M	$38,000 0.0% of portfolio	43,108	Q1 2025 Added 6.5%
PMVP Pmv Pharmaceuticals, Inc.	$41.5M	$37,000 0.0% of portfolio	33,600	Q2 2024 Reduced 21.5%
LRMR Larimar Therapeutics, Inc.	$80.9M	$36,000 0.0% of portfolio	16,310	Q1 2025 Added 5.55%
ATOS Atossa Therapeutics, Inc.	$105M	$35,000 0.0% of portfolio	51,198	Q4 2024 Added 25.58%
CRBU Caribou Biosciences, Inc.	$62.1M	$33,000 0.0% of portfolio	35,848	Q4 2024 Added 28.76%
MGNX Macrogenics Inc	$92.8M	$33,000 0.0% of portfolio	25,652	Q1 2025 Reduced 94.72%
LCTX Lineage Cell Therapeutics, Inc.	$119M	$33,000 0.0% of portfolio	72,398	Q1 2025 Reduced 33.09%
FATE Fate Therapeutics Inc	$113M	$31,000 0.0% of portfolio	38,049	Q4 2024 Reduced 41.66%
TNGX Tango Therapeutics, Inc.	$162M	$31,000 0.0% of portfolio	22,252	Q1 2025 Added 5.97%
PDSB Pds Biotechnology Corp	$45M	$30,000 0.0% of portfolio	24,900	Q2 2024 Added 41.97%
STRO Sutro Biopharma, Inc.	$48M	$25,000 0.0% of portfolio	36,893	Q1 2025 Added 22.17%
ENOB Enochian Biosciences Inc	$244M	$25,000 0.0% of portfolio	45,198	Q4 2024 Added 183.46%
PYXS Pyxis Oncology, Inc.	$43.2M	$23,000 0.0% of portfolio	22,220	Q1 2025 Added 41.35%
BDTX Black Diamond Therapeutics, Inc.	$73M	$22,000 0.0% of portfolio	14,182	Q4 2024 Reduced 96.27%
ADGI Adagio Therapeutics, Inc.	$505M	$22,000 0.0% of portfolio	35,716	Q1 2025 Added 38.65%
MRSN Mersana Therapeutics, Inc.	$34M	$22,000 0.0% of portfolio	62,093	Q4 2024 Reduced 37.33%
TCRX T Scan Therapeutics, Inc.	$26.1M	$22,000 0.0% of portfolio	15,479	Q4 2024 Added 25.84%
ATNM Actinium Pharmaceuticals, Inc.	$41.3M	$21,000 0.0% of portfolio	12,785	Q1 2025 New
INZY Inozyme Pharma, Inc.	$159M	$18,000 0.0% of portfolio	19,533	Q4 2024 Added 17.65%
APLT Applied Therapeutics Inc.	$19.7M	$17,000 0.0% of portfolio	34,763	Q4 2024 Reduced 96.59%
ABOS Acumen Pharmaceuticals, Inc.	$41.3M	$15,000 0.0% of portfolio	13,616	Q4 2024 Reduced 98.4%
HLVX Hille Vax, Inc.	$62.2M	$15,000 0.0% of portfolio	10,063	Q2 2024 New
NAUT Nautilus Biotechnology, Inc.	$91M	$14,000 0.0% of portfolio	16,078	Q1 2024 Added 35.81%
STTK Shattuck Labs, Inc.	$45.8M	$12,000 0.0% of portfolio	12,603	Q4 2024 Reduced 60.5%
IPSC Century Therapeutics, Inc.	$33M	$8,000 0.0% of portfolio	14,882	Q2 2024 New
ALXO Alx Oncology Holdings Inc	$18.7M	$7,000 0.0% of portfolio	10,622	Q2 2024 Reduced 95.44%
OVID Ovid Therapeutics Inc.	$20.4M	$6,000 0.0% of portfolio	17,396	Q1 2024 Added 22.07%
ELEV Elevation Oncology, Inc.	$7.46M	$5,000 0.0% of portfolio	16,841	Q2 2024 New
LYRA Lyra Therapeutics, Inc.	$2.86M	$3,000 0.0% of portfolio	17,541	Q2 2024 New
SRZNW Surrozen Inc Wt Exp 08/01/31 (	$0	$2,000 0.0% of portfolio	41,666	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.